Physician profile
Steven Coppock
NPI 1164635926
$3,921.27
in general payments reported to CMS, 2019-2025
30 companies · $1,431 in 2025
The $1,431 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $142 · 2021: $402 · 2022: $133 · 2023: $150 · 2024: $1,553 · 2025: $1,431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,133.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $908.03 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Novo Nordisk INC | $759.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $442.61 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $312.14 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $279.40 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $146.19 | 2020-2025 | Rexulti |
| Amgen INC. | $111.10 | 2024-2025 | Krystexxa, Otezla, Repatha |
| Ucb, INC. | $104.49 | 2024 | Briviact, Nayzilam |
| Axsome Therapeutics, INC. | $95.81 | 2025 | Auvelity |
| Corium, LLC | $86.78 | 2024-2025 | Azstarys |
| Esperion Therapeutics, INC. | $76.14 | 2024-2025 | Nexletol |
| Exact Sciences Corporation | $62.11 | 2024-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $52.17 | 2023-2025 | Caplyta |
| Tandem Diabetes Care, INC. | $49.44 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.37 | 2019-2025 | Jardiance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $44.76 | 2024-2025 | Dyanavel Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.11 | 2019-2021 | |
| Z-Medica, LLC | $36.76 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.27 | 2025 | Trintellix |
| Currax Pharmaceuticals LLC | $32.63 | 2024 | Contrave |
| Insulet Corporation | $30.39 | 2025 | Omnipod |
| Kowa Pharmaceuticals America, INC. | $27.07 | 2020-2022 | |
| Galderma Laboratories, L.P. | $26.80 | 2021 | |
| Antares Pharma, INC. | $19.77 | 2025 | Xyosted |
| Allergan, INC. | $17.75 | 2021 | |
| Atland Pharmaceuticals, LLC | $16.43 | 2025 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
| Merck Sharp & Dohme LLC | $15.91 | 2020 | |
| Glaxosmithkline, LLC. | $14.55 | 2024 | Trelegy Ellipta |
| Abbott Laboratories | $14.55 | 2023 | Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $14.33 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Coppock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.